Radiance Pharmaceutical

Radiance Therapeutics is a clinical-stage biotechnology company focused on developing innovative ophthalmic therapies to improve outcomes in glaucoma surgery. The company's lead product is the Radiance Beta Therapy System, a novel application of beta radiation designed to prevent scarring (fibrosis) following glaucoma filtration surgery (trabeculectomy). By delivering a precise, localized dose of beta radiation to the surgical site, the system aims to inhibit the proliferation of fibroblasts that cause bleb failure, the primary reason for surgical complications in glaucoma patients. Radiance Therapeutics is currently advancing its technology through clinical trials to provide a safer and more effective alternative to traditional anti-metabolites like mitomycin-C.